Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human TNFSF11 Antibodies:
anti-Mouse (Murine) TNFSF11 Antibodies:
anti-Rat (Rattus) TNFSF11 Antibodies:
Go to our pre-filtered search.
Human Monoclonal TNFSF11 Primary Antibody for ChIP, FACS - ABIN252476
Kikuchi, Matsuguchi, Tsuboi, Mitani, Tanaka, Matsuoka, Yamamoto, Hishikawa, Noguchi, Yoshikai: Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors. in Journal of immunology (Baltimore, Md. : 1950) 2001
Show all 21 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody for IF (p), IHC (p) - ABIN672696
Yang, Li, Yang, Shen, Zou, Zhu, Zhang, Yang, Li: Efficacy and safety of echinacoside in a rat osteopenia model. in Evidence-based complementary and alternative medicine : eCAM 2013
Show all 15 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody for IF (p), IHC (p) - ABIN668556
Zhang, Liu, Li, Bai: Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-?B ligand and osteoprotegerin in human osteoblasts. in Experimental and therapeutic medicine 2015
Show all 11 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody for ChIP, CyTOF - ABIN252546
Hsu, Lacey, Dunstan, Solovyev, Colombero, Timms, Tan, Elliott, Kelley, Sarosi, Wang, Xia, Elliott, Chiu, Black, Scully, Capparelli, Morony, Shimamoto, Bass, Boyle: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. in Proceedings of the National Academy of Sciences of the United States of America 1999
Show all 11 Pubmed References
Mouse (Murine) Monoclonal TNFSF11 Primary Antibody for IHC (fro), FACS - ABIN2479510
Andersen, Jørgensen, Bardram, Hilsted: Screening for multiple endocrine neoplasia type 1 in patients with recognized pituitary adenoma. in Clinical endocrinology 1991
Show all 4 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody for FACS, IHC (fro) - ABIN252684
Yoneda, Ishimaru, Arakaki, Kobayashi, Izawa, Moriyama, Hayashi: Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. in Endocrinology 2004
Show all 3 Pubmed References
Human Monoclonal TNFSF11 Primary Antibody for CyTOF, FACS - ABIN4361916
Shetty, Pepin, Charest, Perron, Doyle, Voisine, Dagenais, Pibarot, Mathieu: Expression of bone-regulatory proteins in human valve allografts. in Heart (British Cardiac Society) 2006
Show all 3 Pubmed References
Human Polyclonal TNFSF11 Primary Antibody for IHC, IHC (p) - ABIN4361905
Lim, Liu, Hunter, Cheng, Mah, Helms: Downregulation of Wnt causes root resorption. in American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2014
Show all 2 Pubmed References
RANKL/OPG ratio was significantly higher in the prolactinoma group than in the control group.
RANKL mRNA expression was higher in tumour tissue from patients with metastatic prostate cancer compared to local disease. The RANKL/OPG ratio was low in normal prostate tissue and high in tumours with bone metastases. Expression was high in BPH (show GLI3 Antibodies) tissue but did not exceed as much as in the tumour tissue.
In cardiovascular risks, OPG (show TNFRSF11B Antibodies) serum level might increase as a preventive compensatory mechanism to neutralize the RANKL level increment. The determination of the OPG-RANKL system is a diagnostic indicator for the intensity of vascular calcification and atherosclerosis in SSc (show CYP11A1 Antibodies) patients.
sRANKL and OPG (show TNFRSF11B Antibodies) may play a role in the pathogenesis of diabetes as well as metabolic disturbance
regulation of OSCAR by TNF-alpha (show TNF Antibodies) and receptor activator of NF kappa beta ligand (RANKL) in pre-osteoclasts/osteoclasts
The -643C>T RANKL polymorphism, through its significant influence on body weight and BMI value, may contribute to the development of Osteoporosis in Postmenopausal women.
In the present study, we measured expression of RANKL in human periosteum-derived cells(hPDCs) undergoing osteoblastic differentiation and found that expression of RANKL mRNA was markedly increased in these cells in a time-dependent manner.RANKL protein expression was also significantly enhanced in osteogenic-conditioned media from hPDCs undergoing osteoblastic differentiation
MiR (show MLXIP Antibodies)-217 is a useful diagnostic biomarker and is involved in human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy.
Vascular smooth cells are a significant source of osteoprotegerin (show TNFRSF11B Antibodies) within the vasculature but that RANKL, once present, downregulates this production and appears capable of preventing the "protective" upregulation of OPG (show TNFRSF11B Antibodies) seen with VSMCs exposed to physiological levels of cyclic strain.
receptor activator for nuclear factor-kappa B ligand (RANKL), secreted by human embryonic trophoblasts and maternal decidual stromal cells, polarizes decidual macrophages toward a M2 phenotype.
although TNFalpha does not induce osteoclastogenesis alone, it does work with RANKL to induce osteoclastic differentiation, and the NFkappaB pathway may serve an important role in this process.
the investigation of RANK and RANKL as possible novel immunotherapy targets in cancer is a rational approach. Here we have defined the mechanism of action of RANKL-RANK blockade in combination with anti-CTLA4 (show CTLA4 Antibodies), and provide insight into the combination efficacy observed in the case reports.
the molecular level, we confirmed, for the first time, that RES upregulated FoxO1 (show FOXO1 Antibodies) transcriptional activity by inhibiting the PI3K/AKT (show AKT1 Antibodies) signaling pathway, and hence promoted resistance to oxidative damage and restrained osteoclastogenesis. Inhibition of the PI3K/AKT (show AKT1 Antibodies) signaling pathway may be induced by RANKL.
Deletion of the RANKL D5 enhancer delays the progression of atherosclerotic plaque development and plaque calcification in hypercholesterolemic mice.
these results suggest that A2BAR (show ADORA2B Antibodies) stimulation inhibits the activation of ERK1/2, p38 (show CRK Antibodies) and NF-kappaB (show NFKB1 Antibodies) by RANKL, which suppresses the induction of osteoclast marker genes, thus contributing to the decrease in osteoclast cell-cell fusion and bone resorption activity.
CD11b (show ITGAM Antibodies) promotes the differentiation of osteoclasts induced by RANKL through the Syk (show SYK Antibodies) signaling pathway.
RANKL and Src (show SRC Antibodies) has an unrecognized role in osteocyte survival.
compressive force induced the differentiation of RAW264.7 from increase in RANK and decrease in LGR4 (show LGR4 Antibodies) expression.
miR (show MLXIP Antibodies)-145 expression was inhibited in RANKL-induced osteoclastogenesis
LPS (show TLR4 Antibodies) increased mRNA and protein expressions of IL-6 (show IL6 Antibodies) and RANKL on day 14
This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found.
TNF-related activation-induced cytokine
, osteoclast differentiation factor
, osteoprotegerin ligand
, receptor activator of nuclear factor kappa B ligand
, receptor activator of nuclear factor kappa-B ligand
, tumor necrosis factor ligand superfamily member 11
, tumor necrosis factor (ligand) superfamily, member 11
, Receptor activator of nuclear factor kappa-B ligand
, OPG ligand
, receptor activator of NF-kappaB ligand
, tumor necrosis factor-related activation-induced cytokine
, TNF superfamily member 11 L homeolog
, tumor necrosis factor superfamily member 11 L homeolog